Dr. Malley received his early education at Ecole Active Bilingue in Paris France, then a BA from Yale University, MD from Tufts University, and pediatrics, pediatric infectious diseases, and emergency medicine training at Boston Children’s Hospital (BCH). A chance meeting with Dr. Porter Anderson led to his interest in developing a universal pneumococcal vaccine and vaccinology in general. Under Dr. Anderson’s mentorship, he shifted his research to the discovery and development of vaccines.

In addition to his clinical activities, attending inpatient Infectious Diseases consult service and directing the Travel and Geographic Medicine clinic at BCH, he runs a research laboratory funded by the NIH, PATH, and the Gates Foundation.

In 2014, Dr. Malley and collaborators started Affinivax, a biotechnology company based on a novel technology called MAPS (Multiple Antigen Presenting System) to develop vaccines for both developed and developing countries. He was a board member and CSO of Affinivax. When the company was acquired by GSK in August 2022, he became Chief MAPS scientist, a role he held until March 31, 2023, after which he returned full-time to Boston Children’s Hospital.